anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Hydromorphone
Trial phase: Phase 4
ATC code: N02AA03 | N02AA53 | N02AG04
SMILES: [H][C@@]12CCC(=O)[C@]3([H])Oc4c(O)ccc5c4[C@]13CCN(C)[C@]2([H])C5
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 28
Group description: Patients in the control arm (Group C) will not receive acetaminophen for 24 hours.

Hydromorphone

No adverse events.
Eligibility criteria:
Inclusion Criteria:

ASA (American Society of Anesthesiologists) I-III patients scheduled for elective one or two level minimally invasive lumbar fusions

Exclusion Criteria:

Patients requiring surgery for neoplastic processes
Allergy to acetaminophen
Liver dysfunction and elevated Liver Function Tests (LFTs)
Alcohol or drug dependency
Mental retardation
Less than 50 kg of weight
regnant women
Patients requiring long-acting opioid pain management (including fentanyl patch, oxycontin, etc) for over 3 weeks immediately prior to surgery
Intervention: TERLIPRESSIN
Trial phase: Phase 2
ATC code: H01BA04
SMILES: NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 6
Group description: Continuous infusion of terlipressin starting at 2 mg/day over 7 days in-house and if tolerated continue treatment in the ambulatory setting for 21 days

Terlipressin acetate continuous infusion: Low-dose continuous infusion of Terlipressin administered via ambulatory pump over 28 days
Eligibility criteria:
Inclusion Criteria:

Patients with cirrhosis and refractory ascites who required 3 or more large volume (4 liters and more) paracenteses in the previous 60 days

Exclusion Criteria:

Ascites with causes other than cirrhosis such as nephrogenic ascites or malignant ascites due to peritoneal carcinomatosis
Total bilirubin > 5 mg/dL
Blood clotting International normalized ratio (INR) > 2.5
Serum creatinine > 2.0 mg/dL
Current or recent (within 3 months of consent) renal dialysis
Hepatic encephalopathy grade 3 or 4
Superimposed acute liver failure/injury due to factors other than alcoholic hepatitis, including acute viral hepatitis, drugs, medications (e.g., acetaminophen), or other toxins (e.g., mushroom [Amanita] poisoning)
Current or recent treatment (within 7 days) with octreotide, midodrine, vasopressin, dopamine or other vasopressors
Respiratory failure requiring positive airway pressure devices or intubation
SIRS/sepsis episode in the previous 28 days from consent
Episode of spontaneous bacterial peritonitis or gastrointestinal hemorrhage within 28 days of consent
Ongoing documented or suspected infection
Severe cardiovascular disease that are contraindication to terlipressin therapy such as advanced arteriosclerosis, arrhythmia, coronary insufficiency or uncontrolled hypertension
Findings suggestive of organic renal disease (severe proteinuria/hematuria, or abnormal renal ultrasound suggestive of obstructive or other renal pathology)
Severe comorbidity that in the opinion of the Investigator would affect short-term prognosis and/or disallow safe participation in the trial (such as for example, severe anemia or pancytopenia, advanced neoplasia, hepatocellular carcinoma [confirmed with serum alpha1-fetoprotein testing], severe chronic obstructive pulmonary disease or asthma)
Alcoholics who have not been abstinent for the past 6 months
Transjugular intrahepatic portosystemic shunt or other surgical shunt
For female patients: Confirmed pregnancy
Known allergy or hypersensitivity to terlipressin
Participation in other clinical research studies involving the evaluation of other investigational drugs or devices within 30 days of consent.
Intervention: Lidocaine
Trial phase: Phase 4
ATC code: C01BB01 | C05AD01 | D04AB01 | N01BB02 | N01BB52 | R02AD02 | S01HA07 | S02DA01
SMILES: CCN(CC)CC(=O)Nc1c(C)cccc1C
Sex: Female
Age groups: Child | Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 98
Group description: A paracervical block will be administered with 20 cc of 1% lidocaine, which is our standard office protocol

Lidocaine: Paracervical block will be injected at 2 points at the cervicovaginal junction to decrease pain
Eligibility criteria:
Inclusion Criteria:

Pregnant women 14 years and older
Desiring uterine aspiration for pregnancy or surgical management of a miscarriage
Gestational age up to 13 weeks and 6 days to be established by best dating (i.e. last menstrual period or earliest ultrasound)
Treatment plan involves outpatient uterine aspiration
Participant able to provide informed consent in English and willing to participate in the study

Exclusion Criteria:

Unable to read, speak, or understand English
Unable to provide informed consent
Currently incarcerated
Under the age of 14 years
Contraindications to receiving lidocaine or buffered lidocaine
Intervention: Sitagliptin
Trial phase: Phase 4
ATC code: A10BD07 | A10BD12 | A10BD24 | A10BH01 | A10BH51
SMILES: N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 71
Group description: Patients in this group will accept Sitagliptin phosphate tablets as their intervention. Specifications: Each tablet 100mg (with sitagliptin dollars). Regimen: The recommended dose is 100mg.QD for 3 months.

Sitagliptin: 100mg.QD for 3 months
Eligibility criteria:
For Sitagliptin group--

Inclusion Criteria:

According to diagnostic criteria from Chinese type 2 diabetes prevention and treatment guidelines in diabetes, that published in the Chinese Medical Association Diabetes credits in 2010: Symptoms of diabetes (polydipsia, polyphagia, polyuria, weight loss, itchy skin, blurred vision and other acute metabolic disorders performance caused by hyperglycemia) and RBG≥11.1mmol/L, or fasting plasma glucose (FPG)≥7.0mmol/L, or plasma glucose of 2 hours post glucose-load≥11.1 and patients diagnosed with type 2 diabetes; HbA1c in the range of 7%-10%;
Age 40-70 years;
Body Mass Index(BMI) 18-40;
Did not accepted any antihyperglycemic therapies during the past 4 weeks, or did not change their antihyperglycemic treatment plan in the past 3 months;
Did not participate in clinical trials within three months;
No serious heart, brain, liver and kidney disease;
Signed informed consent.

Exclusion Criteria:

Have taken any incretin drugs within recent 1 month;
Patients with a weakened immune system;
C-peptide < 0.3ng/ml;
GLP-1 and DPP4-i drugs allergies;
Pregnancy and breast-feeding patients;
Patients taking drugs that may affect the metabolism of GLP-1 and DPP4;
Patients have serious heart, liver, kidney and respiratory dysfunction; Patients have medullary thyroid carcinoma (MTC) with past history or family history, as well as multiple endocrine neoplasia type 2 syndrome (MEN2);
Drug abusing and alcoholism within a year.

For non-T2D group--

No major diseases such as tumors, no dyslipidemia, chronic diseases such as hypertension, and non-diabetic patients whose blood sugar and glycated hemoglobin values cannot meet the criteria for diagnosis of T2DM, and the age is over 50 years old.
Intervention: Ketamine
Trial phase: Phase 2 | Phase 3
ATC code: N01AX03 | N01AX14 | N06AX27
SMILES: CNC1(c2ccccc2Cl)CCCCC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 9
Group description: OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion.

Ketamine: OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion in which dosage will be based on ideal or adjust body weight
Eligibility criteria:
Inclusion Criteria:

aged 19-100
scheduled to undergo general ENT or Orthopedic Surgery
diagnosis of obstructive sleep apnea as confirmed by sleep study or deemed high risked for obstructive sleep apnea by clinical predictors (greater than 4 clinical predictors of obstructive sleep apnea as described by STOP BANG ).

Exclusion Criteria:

positive pregnancy test
ASA > III
history of alcohol or narcotic abuse in last 90 days
significant cardiovascular or respiratory disease (baseline oxygen saturation below 92%)
significant psychiatric or neurologic disease
history of significant hepatic or renal disease (baseline creatinine>1.5)
history of allergy or contraindication to anesthetic agents or ketamine including patients with increased ICP
increased IOP
severe arrhythmias
history of delirium
history of hallucinations
history of psychosis
history of uncontrolled seizures
potential risk for malignant hyperthermia (family history)
history of difficult intubation that would preclude standard induction of anesthesia
prisoners
persons who are mentally impaired
non-English speakers
Intervention: Bupivacaine
Trial phase: Phase 3
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 45
Group description: Subjects will receive 10 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl.

10 mg Bupivacaine: 10 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl injected to the epidural space
Eligibility criteria:
Inclusion Criteria:

Patients undergoing short obstetric procedure in the operating room requiring neuraxial anesthesia.

Exclusion Criteria:

coagulopathy
platelets <80,000
allergy to local anesthetic or fentanyl
previous spinal surgery
spinal or intracranial mass
history of lower extremity weakness
Intervention: Bupivacaine
Trial phase: Phase 3
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 45
Group description: Subjects will receive 5 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl in combination with 10 mL of sterile saline injected into the epidural space.

5 mg Bupivacaine: 5 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl in combination with 10 mL of sterile saline injected into the epidural space.
Eligibility criteria:
Inclusion Criteria:

Patients undergoing short obstetric procedure in the operating room requiring neuraxial anesthesia.

Exclusion Criteria:

coagulopathy
platelets <80,000
allergy to local anesthetic or fentanyl
previous spinal surgery
spinal or intracranial mass
history of lower extremity weakness
Intervention: Efinaconazole
Trial phase: Phase 4
ATC code: D01AC19
SMILES: C=C1CCN([C@H](C)[C@](O)(Cn2cncn2)c2ccc(F)cc2F)CC1
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 13
Group description: The control group was comprised of women who agreed to abstain from wearing toenail polish throughout the length of the study.

Inclusion criteria consisted of being female and aged 19-70 with DLSO effecting at least one great toenail. The target great toenail thickness was less than or equal to 3mm. DLSO was diagnosed by having a positive potassium hydroxide microscopy and culture of a dermatophyte. Exclusion criteria included a history of either immunosuppression, uncontrolled diabetes mellitus, or psoriasis. Patients were also excluded if they had severe target toenail DLSO or three or more dermatophytomas on the target toenail. Patients were required to refrain from wearing gel or plastic based polishes that are used in salons and require curing.

Patients with symptomatic tinea pedis at screening were treated with luliconazole cream for 2 weeks.
Eligibility criteria:
Inclusion Criteria:

Female age 19-70, as 19 is the legal age in Alabama
DLSO affecting at least 1 great toenail diagnosed with positive potassium hydroxide microscopy and culture of a dermatophyte
Suitable for application of topical antifungal therapy, in the opinion of the investigator
Target toenail thickness of 3 mm or less as measured by digital caliper, as thickness greater than 3 mm may allow inclusion of patient with severe onychomycosis, and this was the criteria used in the pivotal trial using topical efinaconazole for onychomycosis
Women of childbearing potential will be required to use birth control and a negative urine pregnancy test must be documented prior to initiating treatment

Exclusion Criteria:

History of immunosuppression or concurrent use of immunosuppressant drugs
History of uncontrolled diabetes mellitus
History of psoriasis or any other condition that might interfere with the toenail evaluation
Three or more dermatophytomas (streaks) on the target nail
Severe DLSO of the target nail
Patients who cannot refrain from wearing gel or plastic based polishes that are used in salons and that require curing
Intervention: Racivir
Trial phase: Phase 3
ATC code: J05AF09 | J05AR03 | J05AR06 | J05AR08 | J05AR09 | J05AR17 | J05AR18 | J05AR19 | J05AR20 | J05AR22
SMILES: Nc1nc(=O)n(C2CSC(CO)O2)cc1F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 125
Group description: Participants who received B/F/TAF in double-blind phase and from a country where B/F/TAF was not available were given the option to receive B/F/TAF orally once daily for up to 96 weeks in the open-label extension phase.
Eligibility criteria:
Key Inclusion Criteria:

Currently receiving an ARV regimen of DTG+F/TAF or DTG+F/TDF for the following minimum time periods:

≥ 6 months (if there is documented or suspected nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) resistance prior to the screening visit)
≥ 3 months (if there is no documented or suspected NRTI resistance prior to the screening visit)
Documented plasma HIV-1 ribonucleic acid (RNA) < 50 copies/mL during treatment with DTG+F/TAF or DTG+F/TDF (for a minimum period of ≥ 6 or ≥ 3 months, as applicable) preceding the screening visit
Plasma HIV-1 RNA levels < 50 copies/mL at screening visit
Estimated Glomerular Filtration Rate (eGFR) ≥ 30 mL/min according to the Cockcroft-Gault formula for creatinine clearance
No documented resistance to integrase stand transfer inhibitors (INSTIs) or confirmed virologic failure
Eligible adults with chronic hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection are permitted to enroll

NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Intervention: Racivir
Trial phase: Phase 3
ATC code: J05AF09 | J05AR03 | J05AR06 | J05AR08 | J05AR09 | J05AR17 | J05AR18 | J05AR19 | J05AR20 | J05AR22
SMILES: Nc1nc(=O)n(C2CSC(CO)O2)cc1F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 116
Group description: Participants who received DTG + F/TAF in double-blind phase and from a country where B/F/TAF was not available were given the option to receive B/F/TAF orally once daily for up to 96 weeks in the open-label extension phase.
Eligibility criteria:
Key Inclusion Criteria:

Currently receiving an ARV regimen of DTG+F/TAF or DTG+F/TDF for the following minimum time periods:

≥ 6 months (if there is documented or suspected nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) resistance prior to the screening visit)
≥ 3 months (if there is no documented or suspected NRTI resistance prior to the screening visit)
Documented plasma HIV-1 ribonucleic acid (RNA) < 50 copies/mL during treatment with DTG+F/TAF or DTG+F/TDF (for a minimum period of ≥ 6 or ≥ 3 months, as applicable) preceding the screening visit
Plasma HIV-1 RNA levels < 50 copies/mL at screening visit
Estimated Glomerular Filtration Rate (eGFR) ≥ 30 mL/min according to the Cockcroft-Gault formula for creatinine clearance
No documented resistance to integrase stand transfer inhibitors (INSTIs) or confirmed virologic failure
Eligible adults with chronic hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection are permitted to enroll

NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Intervention: Seliforant
Trial phase: Phase 2
SMILES: CNC1CN(c2cc(N)nc(CC(C)C)n2)C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 36
Group description: SENS-111 100mg: 2 Oral Dispersible Tablets (1 SENS-111 100 mg and 1 placebo)

SENS-111 100mg: SENS-111 100mg is presented as 1 Oral Dispersible Tablet of SENS-111 100mg + 1 Oral Dispersible Tablet of placebo given twice on Day 1, second intake given approximately 12 hours (9 to 15 hours) after the first intake and thereafter given once daily on Days 2 to 5 inclusive. The corresponding total dose will be 500 mg for the entire study.
Eligibility criteria:
Inclusion criteria includes, but is not limited to:

* Subject has a diagnosis of definite Acute Unilateral Vestibulopathy

Exclusion criteria includes, but is not limited to:

Acute continuous vertigo lasting more than 72 hours prior to randomization
History of acute or chronic vestibular diseases
History of prior acute central vestibular lesion
Acute or chronic disease of middle ear
Intervention: Seliforant
Trial phase: Phase 2
SMILES: CNC1CN(c2cc(N)nc(CC(C)C)n2)C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 36
Group description: SENS-111 200mg: 2 Oral Dispersible Tablets (SENS-111 100 mg)

SENS-111 200mg: SENS-111 200mg is presented as 2 Oral Dispersible Tablet of SENS-111 100mg given twice on Day 1,second intake given approximately 12 hours (9 to 15 hours) after the first intake and thereafter given once daily on Days 2 to 5 inclusive. The corresponding total dose will be 1000 mg for the entire study.
Eligibility criteria:
Inclusion criteria includes, but is not limited to:

* Subject has a diagnosis of definite Acute Unilateral Vestibulopathy

Exclusion criteria includes, but is not limited to:

Acute continuous vertigo lasting more than 72 hours prior to randomization
History of acute or chronic vestibular diseases
History of prior acute central vestibular lesion
Acute or chronic disease of middle ear
Intervention: Loxapine
Trial phase: Phase 4
ATC code: N05AH01
SMILES: CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 2
Group description: Inhaled loxapine 10mg + IM normal saline

Loxapine: loxapine + placebo
Eligibility criteria:
Inclusion Criteria:

Requires treatment for agitation in the judgment of a physician
Patient either pre-consented, has surrogate consent, or able to consent (in cases of mild agitation).
The patient is at least 18 years of age and less than 65 years of age.
Patients with known or presumed schizophrenia or bipolar 1 disorder.

Exclusion Criteria:

Patients with acute respiratory signs/symptoms (eg, wheezing).
Known diagnosis of Chronic Obstructive Pulmonary Disease (COPD) or asthma or taking meds for asthma or COPD.
Female patients who are obviously pregnant or breast-feeding.
Medically unstable patients.
Patients or surrogates who object to being in the study (even if previously pre-consented).
Physician objection to patient enrollment in the study.
Prisoners or incarcerated.
Intervention: Ketorolac Tromethamine
Trial phase: Phase 2
SMILES: NC(CO)(CO)CO.O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 94
Group description: The intervention group in this study will receive a one-time dose of Ketorolac 30mg intravenously after undergoing general anesthesia. Because the participants will be under general anesthesia, they will not know if they received the medication. The surgeon will also be blinded to this. The anesthesiologist will not be blinded as he/she will deliver the agent and because the use of Toradol may alter their usage of other intra-operative agents and post-operative agents

Toradol: IV toradol
Eligibility criteria:
Inclusion Criteria:

Undergoing Ureteroscopy for kidney stone management between age 18-80.

Exclusion Criteria:

Unable to provide consent
Contraindications to Toradol
Intervention: RETINOL
Trial phase: Early Phase 1
ATC code: A11CA01 | D10AD02 | R01AX02 | S01XA02 | V04CB01
SMILES: CC1=C(/C=C/C(C)=C/C=C/C(C)=C/CO)C(C)(C)CCC1
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 44
Group description: 0.5% retinol applied to face nightly

Retinol: This group will receive retinol
Eligibility criteria:
Inclusion Criteria:

• Individuals aged 30-55

Exclusion Criteria:

Adults unable to consent
Individuals who are not yet adults (infants, children, teenagers)
Pregnant or breast feeding women
Prisoners
Those with acne, eczema, seborrheic dermatitis, rosacea or polycystic ovarian syndrome
Those who have used isotretinoin in the last 6 months
Those who have used products containing salicylic acid, beta hydroxyl acids or vitamins A, C, or E in the last 14 days
Those who have used topical antibiotics or topical retinoids in the last 30 days
Those who are currently smoking or have smoked within the past 3 years.
Those who have had a recent surgical or cosmetic procedure in the last 3 months that can affect facial wrinkles or facial hyperpigmentation, such as botulinum toxin injections, chemical peels, laser based therapies to the face, or face lift surgeries
Intervention: Sugammadex
Trial phase: Phase 4
ATC code: V03AB35
SMILES: O=C(O)CCSCC1OC2OC3C(CSCCC(=O)O)OC(OC4C(CSCCC(=O)O)OC(OC5C(CSCCC(=O)O)OC(OC6C(CSCCC(=O)O)OC(OC7C(CSCCC(=O)O)OC(OC8C(CSCCC(=O)O)OC(OC9C(CSCCC(=O)O)OC(OC1C(O)C2O)C(O)C9O)C(O)C8O)C(O)C7O)C(O)C6O)C(O)C5O)C(O)C4O)C(O)C3O
Sex: All
Age groups: Older Adult
Healthy volunteers: No
Participants at risk: 19
Group description: 2 mg/kg of sugammadex, IV once at the end of the surgery.

Dosing will be based on actual body weight not ideal body weight.

Sugammadex: once at the end of the surgery
Eligibility criteria:
Inclusion Criteria:

Posterior spinal surgery
Age ≥ 65 years
American Society of Anesthesiologists (ASA) grade I-III

Exclusion Criteria:

Inability to obtain written informed consent
Allergy to rocuronium or anesthetic agents used in the protocol
Known or suspected neuromuscular disorders
Significant renal disease with a serum creatinine ≥ 2 mg/dl
Significant liver disease
A family history of malignant hyperthermia
Intervention: Neostigmine
Trial phase: Phase 4
ATC code: N07AA01 | N07AA51 | S01EB06
SMILES: CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1
Sex: All
Age groups: Older Adult
Healthy volunteers: No
Participants at risk: 21
Group description: 50 micrograms/kg (not to exceed 5 mg) and glycopyrrolate, 10 micrograms/kg (not to exceed 1 mg), IV once at the end of the surgery.

Dosing will be based on actual body weight not ideal body weight.

Neostigmine: once at the end of the surgery
Eligibility criteria:
Inclusion Criteria:

Posterior spinal surgery
Age ≥ 65 years
American Society of Anesthesiologists (ASA) grade I-III

Exclusion Criteria:

Inability to obtain written informed consent
Allergy to rocuronium or anesthetic agents used in the protocol
Known or suspected neuromuscular disorders
Significant renal disease with a serum creatinine ≥ 2 mg/dl
Significant liver disease
A family history of malignant hyperthermia